International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all regions and industry verticals to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.
Global Erythropoietin Drugs Market Research Report 2022-2027:
According to the latest report by IMARC Group, titled " Erythropoietin Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecas t 2022-2027
," the global erythropoietin drugs market size reached US$ 9.8 Billion in 2021.
Erythropoietin (EPO) is a hormone produced naturally by kidneys to stimulate the production of red blood cells (RBCs) in the body. Its deficiency or excess leads to severe medical conditions, such as low hemoglobin levels and kidney diseases. EPO drugs, also known as haematopoietin, are injectable drugs used to cure anemia and increase RBC production.
They are widely used to treat anemic conditions caused by chronic renal disease, cancer treatment, myelodysplasia, medicine side effects, and surgery. They also help reduce infections in acquired immune deficiency syndrome (AIDS) and pre-operative blood transfusion. EPO drugs mimic the naturally occurring erythropoietin and stimulate the bone marrow to produce more RBCs.
Request for a PDF sample of this report:
https://www.imarcgroup.com/erythropoietin-drugs-market/requestsample
The widespread prevalence of chronic diseases, such as cancer, AIDS, and kidney problems, is one of the primary factors driving the market growth. EPO drugs are widely used to treat anemic conditions induced by end-stage renal disease (ESRD), antiretroviral treatments (ART), chemotherapy, radiotherapy, and other cancer treatments. In addition to this, rising product utilization to treat critically ill patients owing to its anti-ischemic, anti-apoptotic, and regenerative effects in various tissues, such as lungs, kidneys, nervous system, pancreas, and retina, is acting as another growth-inducing factor.
Furthermore, the rapid commercialization of highly efficient biosimilars, which are easy to switch, costeffective, and require less approval time, is providing an impetus to the market growth. In line with this, the widespread product application in chemotherapy cycles, along with the increasing incidences of end-stage renal diseases (dialysis), is favoring the market growth. Additionally, the recent repurposing of EPO drugs for treating diabetes mellitus (DM) due to its cytoprotective effect that enhances cardiac function, reduces fatigue, and improves cognition in DM patients is positively influencing the market growth. Moreover, the implementation of various government initiatives to incentivize research on chronic diseases through grants, drug exclusivity, fee waivers, and tax credits is propelling the market growth.
Other factors, including rising awareness regarding the benefits of EPO therapeutics, the increasing geriatric population in need of surgical procedures, and rising strategic collaborations among drug manufacturers due to high return on investment (ROI), are anticipated to drive the market growth.
Looking forward, IMARC Group expects the market to reach US$ 13.8 Billion by 2027, exhibiting at a CAGR of 5.75% during 2022-2027.
View Report TOC, Figures and Tables: https://www.imarcgroup.com/erythropoietin-drugs-market
Key Market Segmentation
The research report includes the following segments:
Breakup by Drug Class:
• Biologics
• Biosimilars
Breakup by Product Type:
• Epoetin-alfa
• Epoetin-beta
• Darbepoetin-alfa
• Others
Breakup by Application:
• Hematology
• Kidney Disorder
• Cancer
• Others
Breakup by End User:
• Hospitals
• Homecare
• Specialty Clinics
• Others
Breakup by Region:
• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa
Competitive Landscape with Key Players:
• Amgen Inc
• Biocon Limited
• Dr. Reddy’s Laboratories Ltd
• F. Hoffmann-La Roche AG
• Intas Pharmaceuticals Ltd
• Johnson & Johnson
• LG Chem Ltd
• Pfizer Inc
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Ltd
1. How has the global erythropoietin drugs market performed so far and how will it perform in the coming years?
2. What has been the impact of COVID-19 on the global erythropoietin drugs market?
3. What are the key regional markets?
4. What is the breakup of the market based on the drug class?
5. What is the breakup of the market based on the product type?
6. What is the breakup of the market based on the application?
7. What is the breakup of the market based on the end user?
8. What are the various stages in the value chain of the industry?
9. What are the key driving factors and challenges in the industry?
10. What is the structure of the global erythropoietin drugs market and who are the key players?
11. What is the degree of competition in the industry?
Click here to visit the complete table of content with list of figures and tables: https://www.imarcgroup.com/erythropoietin-drugs-market/toc
We are the trusted business partners to the world's leading corporates, governments, and institutions
We are the trusted business partners to the world's leading corporates, governments, and institutions
© 2022 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.
